This highly cited publication demonstrated a successful experimental clinical application of MSC-EVs where MSC-EVs decreased probably indirectly numbers of patient-derived peripheral blood cells, which secreted pro-inflammatory cytokines IL-1β, TNFα and IFNγ, likely contributing in modulating patient's immune status that led to significant improvement of clinical GvHD symptoms 38. This evidence concerns the gene TNF and graft versus host disease.